Endo’s Generics Add $30m Due To COVID-19 Impact

Company Sees $75m Overall Growth In Q1 From Coronavirus Demand

 
• By Akriti Seth
  
Growth_Arrow_Pills
Endo’s generics segment saw double-digit growth in the first quarter of 2020 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business